Data compiled by Redley Lamar · ChainSifter Intelligence
11Suppliers
10Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Immunovant, Inc. (IMVT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
25Total relationships
3Distinct source URLs
7High confidence
0.758Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Immunovant, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CROS
CROS
90%
In the normal course of business, the Company enters into agreements with CROs for clinical trials
VENDORS
VENDORS
90%
In the normal course of business, the Company enters into agreements with CROs for clinical trials and with vendors for nonclinical studies, manufacturing and other services and products for operatin…
HANALL
HANALL
80%
We have licensed certain intellectual property rights, including certain intellectual property rights covering IMVT-1402 and batoclimab from HanAll
Reciprocal relationship from ARGX graph: Reciprocal relationship from IMVT graph: gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candida…
gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidates, a less effective biosimilar may be more quickly adopted by physicians and pat…
gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidates, a less effective biosimilar may be more quickly adopted by physicians and pat…
Reciprocal relationship from JNJ graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from IMVT graph: gulated, unapproved and off-label tre…
Reciprocal relationship from ROIV graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from ROIV g…
data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in …
SNYNF
Sanofi
72%
gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidates, a less effective biosimilar may be more quickly adopted by physicians and pat…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMVT graph: gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candid…
Reciprocal relationship from ARGX graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from ARGX graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from ARGX g…
gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidates, a less effective biosimilar may be more quickly adopted by physicians and pat…
Reciprocal relationship from JNJ graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from JNJ grap…
gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidates, a less effective biosimilar may be more quickly adopted by physicians and pat…
Item 1A in this Annual Report. Our Key Agreements License Agreement with HanAll (“HanAll Agreement”) We have commenced discussions with HanAll regarding the future disposition of batoclimab, includin…
Reciprocal relationship from ROIV graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from ROIV g…
SNYNF
Sanofi
72%
gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidates, a less effective biosimilar may be more quickly adopted by physicians and pat…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMVT graph: gulated, unapproved and off-label…
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
62%
ember 31, 2025, interest income decreased $0.6 million as compared with the prior-year period, primarily reflecting lower average interest rates, partially offset by higher average money market fund …
ROIVANT-SCIENCES-GMBH
ROIVANT-SCIENCES-GMBH
62%
Item 1A in this Quarterly Report. Our Key Agreements License Agreement with HanAll (“HanAll Agreement”) We have commenced discussions with HanAll regarding the potential return to HanAll of certain r…
Immunovant, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IMVT-DEBT-10258
Warrants outstanding: 0
90%
xbrl warrant detail from xbrl 2021-03-31.
IMVT-DEBT
Debt stack $72,000
90%
Market cache reports total debt of $72,000.
IMVT-DEBT-10259
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-03-31.
Immunovant, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Immunovant, Inc..
Immunovant, Inc. Ownership
Holder
Name
Confidence
Evidence
IMVT-OWNER-FMR-LLC
FMR LLC
90%
13F overlay lists FMR LLC as top holder; 218 tracked holders.
